BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology Technology to Map Underlying Biology of Patient Responses in Advanced Solid Tumor Trial of BPM31510
Early Phase Study of BPM31510 Demonstrates BERG’s Interrogative Biology Platform Can Identify the Molecular Basis of Efficacy and Adverse Events, Offering Critical Insights for Drug Late-Stage Development from Analyses of Longitudinal Patient Samples
BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease modifying targets, announced results from a predictive analysis of adverse events by the BERG platform, for a multi-center Phase 1 study evaluating BPM31510 (novel ubidecarenone formulation) in 104 patients with advanced relapsed/refractory solid tumors. The findings from the study were presented during a poster session at the European Society for Medical Oncology (ESMO) annual meeting in Barcelona.
“These data add to the growing body of evidence supporting the profound role that our proprietary Interrogative Biology platform can play in drug development,” said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. “Understanding a drug’s comprehensive molecular and pharmacodynamic profile in the early stages of development will allow researchers to create a better risk-management profile of an investigational compound, which might positively impact timelines, development costs, and the potential success of a drug candidate.
Read More: Datameer X Accelerates Machine Learning Analytics and Increases Model Accuracy
The clinical study presented is the first to collect tissue samples and biofluids on a longitudinal basis for a pan-omic analyses at multiple time points on each patient in a solid tumor setting. The goal of the study was to validate that, with the use of systems biology and Bayesian AI platform, BERG would be able to derive biological insights into the mechanism of action of BPM31510 and assess the biological markers or features that may be a predictor to any adverse events and correlate them to the clinical outcome data. BERG’s approach and mission to advance this as a model that will drive much more efficiency in the clinical trial process.
Read More: ADCB Launches Real Time Trade Finance For Customers on dltledgers Blockchain Platform
According to Dr. Vivek Subbiah, the primary investigator of the Phase 1 study at the MD Anderson Cancer Center, “Treatment-emergent events have the potential to derail the development of critical medicines as they can result in patients discontinuing study treatment or dropping out of trials. Insights into the biological basis for potential adverse events (AEs) may allow us to design better clinical trials by addressing the occurrence of these events, either by excluding patient subgroups or incorporating prophylactic interventions for these anticipated events into study design.”
“The data presented indicated that BPM31510 is well tolerated, with safety established at all doses tested as a monotherapy or combination therapy. The antitumor responses presented in the poster point to the potential efficacy of the drug,” said Dr. Linda Vahdat, Professor of Medicine at Weill Cornell Medicine. “The BERG Interrogative Biology® platform has not only provided insights into the molecular pathways elicited by BPM31510 exposure but also an actionable management plan for adverse events.”
